Fingolimod therapy can cause persistent heart rate slowing in patients with preexisting parasympathetic predominance due to autonomic dysfunction. A study of 34 RRMS patients found prolonged ...

After handing Novartis a win in January, a U.S. appeals court has changed course in a Gilenya patent infringement lawsuit. On Tuesday, the judges revived a Chinese drugmaker’s bid to challenge the ...

WASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp's bid to revive a key patent on its blockbuster multiple sclerosis drug Gilenya that was ...

Patients with multiple sclerosis (MS) should be evaluated before, and regularly during, treatment with fingolimod (Gilenya, Novartis) to identify signs and symptoms possibly linked to progressive ...

Novartis NVS plans to file a petition in the U.S. Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing regimen patent. This comes after the U.S. Court of Appeals for the Federal ...

After back-to-back setbacks in its high-stakes Gilenya patent defense, Novartis is taking its arguments all the way to the Supreme Court. Wednesday, Novartis said it plans to petition the Supreme ...

PHILADELPHIA, Pennsylvania — Researchers saw a decrease in macular volume during the first year of fingolimod (Gilenya, Novartis) treatment among patients with multiple sclerosis (MS), according to a ...

The U.S. Court of Appeals for the Federal Circuit has issued its decision upholding the validity of US Patent No. 9,187,405 covering a dosing regimen for Novartis' Gilenya. In August 2020, the U.S.

Please provide your email address to receive an email when new articles are posted on . Cycle Pharmaceuticals announced that the FDA has approved its Tascenso ODT, a bioequivalent to Gilenya, or ...